Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  leukemia
Results 1-25 of 1036 for your search:
Start Over
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia
Status: Not yet active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: Not specified
Trial IDs: E2993T2, NCI-2009-01080, CDR0000529758, ECOG-E2993T2, NCT00899366
A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 200200, NCI-2016-01484, NCT02177812
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: RT12-US-AML-a, NCI-2013-01362, NCT01795924
Cholecalciferol in Treating Patients with Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia with Vitamin D Deficiency
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 556-15, NCI-2015-01502, NCT02553447
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with CD30-Positive Peripheral T-cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 17058, NCI-2017-00573, NCT03113500
Pexidartinib in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Biological Therapy and Gene Therapy in Improving Immune System Recovery After Stem Cell Transplant in Patients With Hematopoietic Cancers
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: DOTTI, NCI-2012-01076, H-28256, NCT01494103
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 116183, NCI-2013-02240, NCT01943851
Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients With Suspected Lower Respiratory Tract Infection
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 21 and under
Trial IDs: SUP1601, NCI-2017-01096, NCT02926612
Individualized High Dose Methotrexate in Treating Younger Patients With Cancer and Significant Risk for Side Effects
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 1 to 22
Trial IDs: H-33119, NCI-2014-00923, NCT02076997
CXCR4 Antagonist BL-8040 and Nelarabine in Treating Patients with Relapsed or Refractory T-Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201606146, NCI-2016-01051, NCT02763384
Engineered Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 60
Trial IDs: 2014-0738, NCI-2016-01915, NCT02960646
Safety Study of Cord Blood Units for Stem Cell Transplants
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Biology and Natural History of Disease Outcomes in Patients with Hematological Malignancies Treated with Donor Stem Cell Transplant
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 0 to 99
Trial IDs: 11-C-0125, NCI-2015-01226, P10753, NCT01326728
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NCT01203722
Adoptive T Cell Therapy in Treating Patients with Cytomegalovirus Infection Occurring after Stem Cell Transplant
Status: Active
Phase: Phase I
Type: Supportive care
Age: 3 months and over
Trial IDs: CASE1Z16, NCI-2016-01990, NCT02982902
Dietary Intervention in Preventing Acute Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Prevention, Supportive care
Age: 10 and over
Trial IDs: UMCC 2016.029, NCI-2016-01415, NCT02763033
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2239.00, NCI-2009-01551, 2239, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099
Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: KX02-01-13, NCI-2015-00135, NCT02326441
Multi-peptide CMV-MVA Vaccine in Reducing CMV Complications in Patients Previously Infected with CMV and Undergoing Donor Hematopoietic Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 to 75
Trial IDs: 14295, NCI-2015-01228, 119132, 121378, 122804, 123127, NCT02506933
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M14-546, NCI-2015-00707, NCT02391480
Baricitinib in Treating Chronic Graft Versus Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Supportive care
Age: 18 to 99
Trial IDs: 16-C-0094, NCI-2016-00773, NCT02759731
Selinexor in Treating Younger Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 months to 21 years
Trial IDs: 13-563, NCI-2014-00936, KPT330, NCT02091245
Targeted Therapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: IRB00007195, NCI-2012-01084, CA180-392, NCT01620216
Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 12 and over
Trial IDs: SHP620-303, NCI-2016-01720, 2015-004725-13, NCT02931539
Start Over